Set for Variability for EEG

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
McGill University, Montreal, Canada
EEG+1 More
Set For Variability - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

The proposed is reading intervention study to track neural changes in the brain. Students with dyslexia will participate in a reading study. Pre and post-analysis data will be obtained to see whether there will be positive neural and behavioural change.

Eligible Conditions

  • EEG

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 10 weeks after baseline

10 weeks after baseline
Physiological parameter using EEG
Standardized reading measures

Trial Safety

Trial Design

2 Treatment Groups

Current best practices
1 of 2
Set for Variability
1 of 2
Active Control
Experimental Treatment

38 Total Participants · 2 Treatment Groups

Primary Treatment: Set for Variability · No Placebo Group · N/A

Set for Variability
Behavioral
Experimental Group · 1 Intervention: Set For Variability · Intervention Types: Behavioral
Current best practices
Behavioral
ActiveComparator Group · 1 Intervention: Current Best Practices · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 weeks after baseline

Trial Background

Armando Bertone, Principal Investigator, Director
Principal Investigator
McGill University
Closest Location: McGill University · Montreal, Canada
Photo of montreal  1Photo of montreal  2Photo of montreal  3
2018First Recorded Clinical Trial
1 TrialsResearching EEG
130 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.